GB2425129A - Cytotrophoblast stem cells - Google Patents
Cytotrophoblast stem cells Download PDFInfo
- Publication number
- GB2425129A GB2425129A GB0606875A GB0606875A GB2425129A GB 2425129 A GB2425129 A GB 2425129A GB 0606875 A GB0606875 A GB 0606875A GB 0606875 A GB0606875 A GB 0606875A GB 2425129 A GB2425129 A GB 2425129A
- Authority
- GB
- United Kingdom
- Prior art keywords
- cell
- cytotrophoblast
- cells
- stem cell
- stem
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000002993 trophoblast Anatomy 0.000 title claims abstract description 143
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 113
- 210000004027 cell Anatomy 0.000 claims abstract description 214
- 238000000034 method Methods 0.000 claims abstract description 63
- 210000002242 embryoid body Anatomy 0.000 claims abstract description 25
- 238000002360 preparation method Methods 0.000 claims abstract description 23
- 239000000203 mixture Substances 0.000 claims abstract description 22
- 102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 claims abstract description 17
- 108010024164 HLA-G Antigens Proteins 0.000 claims abstract description 17
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 16
- 210000001671 embryonic stem cell Anatomy 0.000 claims abstract description 16
- 210000002889 endothelial cell Anatomy 0.000 claims abstract description 14
- 238000002054 transplantation Methods 0.000 claims abstract description 12
- 238000004519 manufacturing process Methods 0.000 claims abstract description 9
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 claims abstract description 7
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 claims abstract description 7
- 229960004407 chorionic gonadotrophin Drugs 0.000 claims abstract description 7
- 238000012258 culturing Methods 0.000 claims abstract description 7
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 7
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 7
- 230000024245 cell differentiation Effects 0.000 claims abstract description 4
- 230000002491 angiogenic effect Effects 0.000 claims abstract description 3
- 210000001519 tissue Anatomy 0.000 claims description 24
- 210000004962 mammalian cell Anatomy 0.000 claims description 22
- 108020004707 nucleic acids Proteins 0.000 claims description 16
- 102000039446 nucleic acids Human genes 0.000 claims description 16
- 150000007523 nucleic acids Chemical class 0.000 claims description 16
- 238000004113 cell culture Methods 0.000 claims description 15
- 239000002609 medium Substances 0.000 claims description 15
- 230000002357 endometrial effect Effects 0.000 claims description 14
- 230000004069 differentiation Effects 0.000 claims description 13
- 210000004602 germ cell Anatomy 0.000 claims description 10
- 210000002950 fibroblast Anatomy 0.000 claims description 9
- 230000001086 cytosolic effect Effects 0.000 claims description 8
- 210000002919 epithelial cell Anatomy 0.000 claims description 8
- 210000005260 human cell Anatomy 0.000 claims description 8
- 241000288906 Primates Species 0.000 claims description 7
- 230000035755 proliferation Effects 0.000 claims description 7
- 239000013598 vector Substances 0.000 claims description 7
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- 239000003636 conditioned culture medium Substances 0.000 claims description 6
- 238000000338 in vitro Methods 0.000 claims description 6
- 102000003969 Fibroblast growth factor 4 Human genes 0.000 claims description 5
- 108090000381 Fibroblast growth factor 4 Proteins 0.000 claims description 5
- 102000005741 Metalloproteases Human genes 0.000 claims description 5
- 108010006035 Metalloproteases Proteins 0.000 claims description 5
- 210000000601 blood cell Anatomy 0.000 claims description 5
- 210000000988 bone and bone Anatomy 0.000 claims description 5
- 210000005175 epidermal keratinocyte Anatomy 0.000 claims description 5
- 230000004927 fusion Effects 0.000 claims description 5
- 230000012010 growth Effects 0.000 claims description 5
- 210000003494 hepatocyte Anatomy 0.000 claims description 5
- 210000003292 kidney cell Anatomy 0.000 claims description 5
- 239000011159 matrix material Substances 0.000 claims description 5
- 210000000663 muscle cell Anatomy 0.000 claims description 5
- 210000003061 neural cell Anatomy 0.000 claims description 5
- 230000001537 neural effect Effects 0.000 claims description 5
- 210000004498 neuroglial cell Anatomy 0.000 claims description 5
- 241000894007 species Species 0.000 claims description 5
- 210000004500 stellate cell Anatomy 0.000 claims description 5
- 238000004458 analytical method Methods 0.000 claims description 4
- 239000000427 antigen Substances 0.000 claims description 4
- 102000036639 antigens Human genes 0.000 claims description 4
- 108091007433 antigens Proteins 0.000 claims description 4
- 239000002299 complementary DNA Substances 0.000 claims description 4
- 238000012544 monitoring process Methods 0.000 claims description 4
- 238000003499 nucleic acid array Methods 0.000 claims description 4
- 101710145634 Antigen 1 Proteins 0.000 claims description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 3
- 102100023974 Keratin, type II cytoskeletal 7 Human genes 0.000 claims description 3
- 108010070507 Keratin-7 Proteins 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 claims description 3
- 102000004576 Placental Lactogen Human genes 0.000 claims description 3
- 108010003044 Placental Lactogen Proteins 0.000 claims description 3
- 239000000381 Placental Lactogen Substances 0.000 claims description 3
- 102000013127 Vimentin Human genes 0.000 claims description 3
- 108010065472 Vimentin Proteins 0.000 claims description 3
- 230000021164 cell adhesion Effects 0.000 claims description 3
- 230000000694 effects Effects 0.000 claims description 3
- 230000003394 haemopoietic effect Effects 0.000 claims description 3
- 229960002897 heparin Drugs 0.000 claims description 3
- 229920000669 heparin Polymers 0.000 claims description 3
- 210000000987 immune system Anatomy 0.000 claims description 3
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 3
- 210000001178 neural stem cell Anatomy 0.000 claims description 3
- 210000005048 vimentin Anatomy 0.000 claims description 3
- 108010035532 Collagen Proteins 0.000 claims description 2
- 102000008186 Collagen Human genes 0.000 claims description 2
- 239000000556 agonist Substances 0.000 claims description 2
- 239000005557 antagonist Substances 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 239000006143 cell culture medium Substances 0.000 claims description 2
- 239000002771 cell marker Substances 0.000 claims description 2
- 230000009391 cell specific gene expression Effects 0.000 claims description 2
- 229920001436 collagen Polymers 0.000 claims description 2
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 2
- 230000001861 immunosuppressant effect Effects 0.000 claims description 2
- 239000003018 immunosuppressive agent Substances 0.000 claims description 2
- 230000004899 motility Effects 0.000 claims description 2
- 210000001665 muscle stem cell Anatomy 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 238000011176 pooling Methods 0.000 claims description 2
- 229920002477 rna polymer Polymers 0.000 claims description 2
- 108010047303 von Willebrand Factor Proteins 0.000 claims description 2
- 102100036537 von Willebrand factor Human genes 0.000 claims description 2
- 229960001134 von willebrand factor Drugs 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 abstract description 2
- 238000012216 screening Methods 0.000 abstract 1
- 102100036495 Di-N-acetylchitobiase Human genes 0.000 description 28
- 101000928786 Homo sapiens Di-N-acetylchitobiase Proteins 0.000 description 28
- 230000014509 gene expression Effects 0.000 description 13
- 210000000056 organ Anatomy 0.000 description 11
- 238000000137 annealing Methods 0.000 description 10
- 230000001464 adherent effect Effects 0.000 description 9
- 238000003501 co-culture Methods 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 9
- 210000002307 prostate Anatomy 0.000 description 8
- 210000002536 stromal cell Anatomy 0.000 description 8
- 210000003932 urinary bladder Anatomy 0.000 description 8
- 210000004347 intestinal mucosa Anatomy 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 210000002200 mouth mucosa Anatomy 0.000 description 6
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 5
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 5
- 102000011782 Keratins Human genes 0.000 description 5
- 108010076876 Keratins Proteins 0.000 description 5
- 230000033115 angiogenesis Effects 0.000 description 5
- 230000007910 cell fusion Effects 0.000 description 5
- 230000002500 effect on skin Effects 0.000 description 5
- 230000003628 erosive effect Effects 0.000 description 5
- 210000002744 extracellular matrix Anatomy 0.000 description 5
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 5
- 210000001161 mammalian embryo Anatomy 0.000 description 5
- 238000003752 polymerase chain reaction Methods 0.000 description 5
- 210000002459 blastocyst Anatomy 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 108010082117 matrigel Proteins 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 101100499263 Dictyostelium discoideum ctbs1 gene Proteins 0.000 description 3
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 3
- 238000004115 adherent culture Methods 0.000 description 3
- 210000004413 cardiac myocyte Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000003511 endothelial effect Effects 0.000 description 3
- 239000005090 green fluorescent protein Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 201000011461 pre-eclampsia Diseases 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 238000002287 time-lapse microscopy Methods 0.000 description 3
- 210000004291 uterus Anatomy 0.000 description 3
- 102000000905 Cadherin Human genes 0.000 description 2
- 108050007957 Cadherin Proteins 0.000 description 2
- 101100499264 Dictyostelium discoideum ctbs2 gene Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 101710201246 Eomesodermin Proteins 0.000 description 2
- 102100030751 Eomesodermin homolog Human genes 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- 102000000424 Matrix Metalloproteinase 2 Human genes 0.000 description 2
- 108010016165 Matrix Metalloproteinase 2 Proteins 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000011712 cell development Effects 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 238000009795 derivation Methods 0.000 description 2
- 210000003981 ectoderm Anatomy 0.000 description 2
- 210000003372 endocrine gland Anatomy 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 210000002304 esc Anatomy 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000029849 luteinization Effects 0.000 description 2
- 210000005075 mammary gland Anatomy 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 210000005088 multinucleated cell Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 230000001817 pituitary effect Effects 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 230000003169 placental effect Effects 0.000 description 2
- 210000005059 placental tissue Anatomy 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 1
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 1
- 102000006277 CDX2 Transcription Factor Human genes 0.000 description 1
- 108010083123 CDX2 Transcription Factor Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 206010056340 Diabetic ulcer Diseases 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 201000009051 Embryonal Carcinoma Diseases 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 208000008899 Habitual abortion Diseases 0.000 description 1
- 101100499266 Homo sapiens CTBS gene Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102000023108 LH Receptors Human genes 0.000 description 1
- 108010011942 LH Receptors Proteins 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 101100445364 Mus musculus Eomes gene Proteins 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 102000037602 Platelet Endothelial Cell Adhesion Molecule-1 Human genes 0.000 description 1
- 108010069381 Platelet Endothelial Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 208000020584 Polyploidy Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000000558 Varicose Ulcer Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 101100445365 Xenopus laevis eomes gene Proteins 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical group 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 230000021953 cytokinesis Effects 0.000 description 1
- 210000003785 decidua Anatomy 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000004578 fetal growth Effects 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000009802 hysterectomy Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000010311 mammalian development Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 210000000110 microvilli Anatomy 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 201000003142 neovascular glaucoma Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 208000018360 neuromuscular disease Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000028742 placenta development Effects 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000001023 pro-angiogenic effect Effects 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 208000034213 recurrent susceptibility to 1 pregnancy loss Diseases 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000017960 syncytium formation Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5064—Endothelial cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5073—Stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/119—Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/31—Pituitary sex hormones, e.g. follicle-stimulating hormone [FSH], luteinising hormone [LH]; Chorionic gonadotropins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Developmental Biology & Embryology (AREA)
- Gynecology & Obstetrics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pregnancy & Childbirth (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Cytotrophoblast stem cells which express HLA-G and HLA class I antigens have been isolated. Preferably, human cytotrophoblast stem cells are derived from human embryonic stem cells, by culturing embryoid bodies and enriching for embryoid bodies expressing high levels of chorionic gonadotrophin. Human cytotrophoblast stem cells may also be isolated by enriching for cytotrophoblast stem cells that express HLA-G and HLA class I antigen. The isolated cytotrophoblast stem cells may be used for tissue engineering, the modulation of tissue rejection in transplantation therapy, the identification of genes associated with cytotrophoblast stem cell differentiation, the preparation of a library of cytotrophoblast stem cell specific gene products, methods of screening agents that modulate the angiogenic effects of endothelial cells, and the production of mixed cell compositions or chimeric cells.
Description
Cytotrophoblast Stem Cell The invention relates to cytotrophoblast stem
cells derived from embryonic stem cells and uses thereof.
During mammalian development those cells that form part of the embryo up until the formation of the blastocyst are said to be totipotent (e.g. each cell has the developmental potential to form a complete embryo and all the cells required to support the growth and development of said embryo). During the formation of the blastocyst, the cells that comprise the inner cell mass are said to be pluripotential (e.g. each cell has the developmental potential to form a variety of tissues).
Embryonic stem cells (i.e. those having the characteristic of pluripotentiality) may be principally derived from two embryonic sources. Cells isolated from the inner cell mass are termed embryonic stem (ES) cells. In the laboratory mouse, similar cells can be derived from the culture of primordial germ cells isolated from the mesenteries or genital ridges of days 8.5-12.5 post coitum embryos. These would ultimately differentiate into germ cells and are referred to as embryonic germ cells (EG cells). Each of these types of pluripotential cell has a similar developmental potential with respect to differentiation into alternate cell types, but possible differences in behaviour (e.g. with respect to imprinting) have led these cells to be distinguished from one another. An indication that conditions may be determined which could allow the establishment of human ES/EG cells in culture is described in W096/22362, which is incorporated by reference. The application describes cell lines and growth conditions which allow the continuous proliferation of primate ES cells which exhibit a range of characteristics or markers which are associated with: ,..:.
stem cells having pluripotent characteristics. * * *
During human implantation the continuous proliferation of cytotrophoblast stem cells (CTB) enables the embryo to rapidly invade the endometrial stroma and establish a: haemochorial placenta. The early differentiation of cytotrophoblast to an invasive *** 1.* endovascular phenotype is critical for promoting feto-matemal immune tolerance and for remodelling uterine blood vessels and aberrant development is associated with serious complications of pregnancy, including recurrent miscarriage, pre-eclampsia (maternal high blood pressure) and restricted fetal growth (1 - 3). This process is poorly understood as investigations with human tissue are severely constrained by ethical and practical considerations.
In the mouse, trophoblast stem cells isolated from the pre- and postimplantation embryo can be maintained indefinitely in culture and have the capacity to differentiate along the trophoblast lineage (4). Rowever, the derivation of human trophoblast stem cells from pre-implantation blastocysts has not been achieved, possibly due to the differences in early embryo development betveen these species (5).
We therefore used human embryonic stem cells (HESCs) as a route to obtaining a trophoblast stem cell population. While HESCs differentiate spontaneously to trophoblast-like cells in cultures (5, 6), when supplemented with bone morphogenetie protein 4 (7) or when Oct 4 is down regulated (8), these cells are terminally differentiated and display a limited proliferative capacity. Trophoblast differentiation can develop further when HESCs are aggregated to form embryoid bodies (EBs) but residual HESCs and other cell types in the culture resulting from spontaneous differentiation confound the findings from these preparations.
We disclose the isolation of these isolated trophoblast-like cells and their maintenance in cell culture. We also disclose the use of these isolated trophoblast- like cells modulation of the immune system and in particular tissue engineering.
Tissue engineering or transplantation has implications with respect to many areas of clinical and cosmetic surgery. More particularly, tissue engineering relates to the replacement and/or restoration and/or repair of damaged and/or diseased tissues to return the tissue and/or organ to a functional state. For example, and not by way of limitation, tissue engineering is useful in the provision of skin grafts to repair wounds occurring as a consequence of: contusions, or burns, or failure of tissue to heal due to venous or diabetic ulcers. Furthermore, tissue engineering is also practised during: replacement of joints through degenerative diseases such as arthritis; replacement of coronary arteries due to damage as a consequence of various environmental causes (e.g. smoking, diet) and/or congenital heart disease including replacement of arterial/heart valve; repair of gastric ulcers; replacement bone tissue resulting from diseases such as osteoporosis; replacement muscle and nerves as a consequence of neuromuscular disease or damage through injury. in addition, organ transplantation has for many years been an established surgical technique to replace damaged and/or diseased organs. The replacement of heart, lung, kidney, liver, bone marrow, and double organ transplantation of, for example, heart and lung, are relatively common procedures.
However, in both tissue engineering and organ transplantation a major obstacle to the successful establishment of a tissue graft or organ transplantation is the host's rejection of the donated tissue or organ.
According to an aspect of the invention there is provided an isolated cytotrophoblast stem cell wherein said stem cell expresses HLA-G and HLA class I antigen.
In a preferred embodiment of the invention said stem cell is mononuclear.
In a further preferred embodiment of the invention said stem cell expresses at least one stem cell marker selected from the group consisting of: cytokeratin 7; stage specific embryonic antigen 1; human placental lactogen; caudal related homeobox; vimentin; and Cd9. : *..:.
In a further preferred embodiment of the invention said stem cell is isolated from a primate, preferably a human. **** J'J 0S**
In a preferred embodiment of the invention said stem cell is not a totipotent cell. S... * S a 3 -
In a preferred embodiment of the invention said stem cell is genetically modified.
It will be apparent to the skilled person that cytotophoblast stem cells may be genetically modified by standard methods which enable the introduction of nucleic acid into a cell either by direct transfection of naked nucleic acid or vector nucleic acid. Alternatively human embryonic stem cells may first be modified and the genetically modified cytotrophoblast stems cells derived by methods hereindisciosed.
A desirable genetically engineered trait would be to transfect human embryonic stem cells or cytotrophoblast stem cells with a nucleic acid encoding a marker gene, for example green fluorescent protein, to allow selection or identification.
According to a further aspect of the invention there is provided a composition comprising cytotrophoblast stem cells for use in tissue engineering.
According to a further aspect of the invention there is provided a culture comprising a cytotrophoblast stem cell according to the invention which culture is contained within a cell culture vessel.
According to a further aspect of the invention there is provided a spheroid body comprising a cytophoblast stem cell according to the invention and a collagen based cell support matrix.
In a preferred embodiment of the invention said cytotrophoblast stem cell in said spheroid body expresses at least one metalloprotease, preferably metalloprotease 2. * *
S.....
According to an aspect of the invention there is provided a method to derive human cytotrophoblast stem cells comprising selectively enriching for cytotrophoblast stem cells that express HLA-G and HLA class 1 antigen. J'J S a... **.S * * S... S...
S S S
According to a further aspect of the invention there is provided a method to derive human cytotrophoblast stem cells from embryonic stem cells comprising the steps of: i) forming embryoid bodies comprising cytotrophoblast cells in a cell culture vessel; ii) identifying those embryoid body cultures which produce greater than about 500m I.U./ml chorionic gonadotrophin; iii) culturing the embryoid bodies identified in (ii) in conditioned media from fibroblast feeder cells; iv) pooling those embryoid bodies which produce greater than about 500m I.U./ml chorionic gonadotrophin and disaggregating said embryoid bodies; and v) repeating (iv) until substantially all embryoid bodies produce high levels of chorionic gonadotrophin.
"Vessel" is defined as any means suitable to contain the above described cell culture.
Typically, examples of such a vessel is a petri dish; cell culture bottle or flask; multiwell culture dishes.
in a preferred method of the invention said conditioned media comprises fibroblast growth factor 4 and heparin.
According to a further aspect of the invention there is provided spent medium produced by culturing the cytotrophoblast stem cells according to the invention.
According to a further aspect of the invention there is provided a method to produce endovascular cytotrophoblast cells comprising the steps of: i) providing a preparation of cytotrophoblast stem cells; * ii) selecting from said preparation a population of cells that express both HLA-G and platelet endothelial cell adhesion molecule-i. a... * I... I...
I S
SI
In a preferred method of the invention said selected cells further express Von Willebrand Factor.
According to a further aspect of the invention there is provided an endovascular cytotrophoblast cell obtained or obtainable by the method of the invention.
In a preferred method of the invention said preparation is cultured under high oxygen tension, preferably at least 5% Co2.
According to a further aspect of the invention, there is provided an in vitro method for the formation of spheroids comprising cytotrophoblast stem cells comprising: i) providing a cell culture vessel comprising: a) cytotrophoblast stem cells according to the invention; b) cell culture medium; and ii) providing conditions which promote the growth and differentiation of said cytotrophoblast stem cells in said spheroid.
According to a further aspect of the invention there is provided spent medium produced by culturing the spheroids comprising cytotrophoblast stem cells according to the invention.
According to a further aspect of the invention there is provided a method for the identification of genes associated with cytotrophoblast stem cell differentiation comprising the steps of: i) providing a preparation comprising at least one cytotrophoblast stem cell according to the invention; ii) extracting nucleic acid from said cell preparation; :.
iii) contacting said extracted nucleic acid with a nucleic acid array; and S iv) detecting a signal which indicates the binding of said nucleic acid to a binding partner on said nucleic acid array. : * S... e.. * S *
Preferably said method includes the additional steps of: i) collating the signal(s) generated by the binding of said nucleic acid to said binding partner; ii) converting the collated signal(s) into a data analysable form; and optionally iii) providing an output for the analysed data.
In a further preferred method of the invention said method includes a comparison of the array signal produced between different populations of cytotrophoblast stem cells isolated from different subjects.
According to a further aspect of the invention there is provided a method for the preparation of a library comprising cytotrophoblast stem cell specific gene expression products comprising the steps: i) providing a preparation comprising at least one cytotrophoblast stem cell according to the invention; ii) extracting nucleic acid from said cell preparation; iii) preparing a cDNA from ribonucleic acid contained in said extracted nucleic acid; and iv) ligating cDNA formed in (iii) into a vector.
In a preferred method of the invention said vector is a phage based vector.
According to a further aspect of the invention there is provided an in vitro method to analyse the invasive properties of cytotrophoblast stem cells comprising the steps of: i) providing a spheroid according to the invention and endometrial *,.ss.
tissue; and:....
ii) monitoring the invasive phenotype of cytotophoblast cells with respect to said endometrial tissue. 30: S... * * S... S * S S. *
According to a further aspect of the invention there is provided a method to identify agents which modulate the angiogenic activity of endothelial cells comprising the steps of: i) providing a preparation of endovascular cytotrophoblast cells according to the invention and an agent to be tested; ii) determining the effect or not of the agent on the proliferation and/or motility of said endovascular cytotrophoblast cells.
In a preferred method of the invention said agent is an antagonist (e.g. an anti- angiogenic agent).
In an alternative method of the invention said agent is an agonist (e.g. a pro- angiogenic agent).
Angiogenesis, the development of new blood vessels from an existing vascular bed, is a complex multistep process that involves the degradation of components of the extracellular matrix and then the migration, cell-division and differentiation of endothelial cells to form tubules and eventually new vessels. Angiogenesis is involved in pathological conditions such as tumour cell growth; non-cancerous conditions such as neovascular glaucoma; inflammation; diabetic nephropathy; retinopathy; rheumatoid arthritis; inflammatory bowel diseases (eg Crohn's disease, ulcerative colitis); and psoriasis. Current endothelial cell-lines used in the analysis of angiogenesis are so called "HuDMECS" which are commercially available endothelial cells. The present invention provides a new model endothelial cell-line useful in the study of angiogenesis. *
I.....
According to an aspect of the invention there is provided the use of a cytotrophoblast * cell, or a cell derived from a cytotrophoblast cell, in the manufacture of a cell composition for use in the modulation of the immune system. S... I... * * I,.. S. * S S. *
According to a further aspect of the invention there is provided the use of a cytotrophoblast cell or a cell derived from a cytotrophoblast cell, in the manufacture of a cell composition for use in the modulation of cellltissue rejection in transplantation therapy.
In a preferred embodiment of the invention said cell is a mammalian cell, preferably a human cell.
According to a further aspect of the invention there is provided a composition comprising an isolated mammalian cytotrophoblast cell, or a cell derived from a cytotrophoblast cell, and at least one further isolated mammalian cell that is not a mammalian cytotrophoblast cell.
In a preferred embodiment of the invention said mammalian cell is a human cell.
In a further preferred embodiment of the invention said cell is selected from the group consisting of: an epidermal keratinocyte; a fibroblast (e. g. dennal, comeal; intestinal mucosa, oral mucosa, bladder, urethral, prostate, liver) an epithelial cell (e.g. comeal, dermal, cornea!; intestinal mucosa, oral mucosa, bladder, urethral, prostate, liver); a neuronal glial cell or neural cell; a hepatocyte stellate cell; a mesenchymal cell; a muscle cell (cardiomyocyte, or myotube cell); a kidney cell; a blood cell (e.g. CD4+ lymphocyte, CD8+ lymphocyte; a pancreatic cell; or an endothelial cell.
In a preferred embodiment of the invention said cell is a pancreatic 3 cell. *
In a further preferred embodiment of the invention said mammalian cell is a stem: : : :* cell.
In a preferred embodiment of the invention said stem cell is selected from the group * consisting of: a haemopoietic stem cell; a neural stem cell; a bone stem cell; a muscle ** I., * * V S. - stem cell; a mesenchymal stem cell; an epithelial stem cell (derived from organs such as the skin, gastrointestinal mucosa, kidney, bladder, mammary glands, uterus, prostate and endocrine glands such as the pituitary); an endodermal stem cell (derived from organs such as the liver, pancreas, lung and blood vessels); an embryonic stem cell; an embryonic germ cell.
In a preferred embodiment of the invention said mammalian cell is an embryonic stem cell or an embryonic germ cell.
Tn a further preferred embodiment of the invention said mammalian cell and said cytotrophoblast cell are autologous.
Preferably said embryonic stem cell/embryonic germ cell are autologous with said cytotrophoblast cell.
In a further preferred embodiment of the invention said composition comprises an additional agent wherein said agent is an immunosuppressant.
According to a further aspect of the invention there is provided a vehicle wherein said vehicle includes a mammalian cytotrophoblast cell, or a cell derived from a cytotrophoblast cell, and at least one further isolated mammalian cell that is not a mammalian cytotrophoblast cell.
Vehicle is defined as any structure to which cells may attach and proliferate.
Examples include a prosthesis, implant, matrix, stent, gauze, bandage, plaster, biodegradable matrix and polymeric film. Matrix material may be synthetic or I iSS naturally occurring and either long-lasting or biodegradable. : * According to a further aspect of the invention there is provided a method to modulate cell/tissue rejection in transplantation therapy comprising: * *1a Ia,, * a S a. 0 i) surgically inserting into an animal a cytotrophoblast cell, or a cell derived from a cytotrophoblast cell and at least one further mammalian cell; and optionally ii) monitoring the immune status of the animal as a measure of the acceptance or otherwise of said mammalian cell.
In a preferred method of the invention said mammalian cell is a human cell.
In a further preferred method of the invention said cell is selected from the group consisting of: an epidermal keratinocyte; a fibroblast (e.g. dermal, corneal; intestinal mucosa, oral mucosa, bladder, urethral, prostate, liver) an epithelial cell (e.g. comeal, dermal, corneal; intestinal mucosa, oral mucosa, bladder, urethral, prostate, liver); a neuronal glial cell or neural cell; a hepatocyte stellate cell; a mesenchymal cell; a muscle cell (cardiomyocyte, or myotube cell); a kidney cell; a blood cell (e.g. CD4+ lymphocyte, CD8+ lymphocyte; a pancreatic f3 cell; or an endothelial cell.
In a further preferred method of the invention said cell is a pancreatic I3 cell.
In a preferred method of the invention said mammalian cell is a stem cell.
In a preferred method of the invention said stem cell is selected from the group consisting of: a haemopoietic stem cell; a neural stem cell; a bone stem cell; a muscle stem cell; a mesenchymal stem cell; an epithelial stem cell (derived from organs such as the skin, gastrointestinal mucosa, kidney, bladder, mammary glands, uterus, prostate and endocrine glands such as the pituitary); an endodermal stem cell (derived from organs such as the liver, pancreas, lung and blood vessels); an embryonic stem cell; an embryonic germ cell. :* :* In a preferred method of the invention said mammalian cell is an embryonic stem cell: or an embryonic germ cell. (I I...
S S S S.
In a further preferred method of the invention said mammalian cell and said cytotrophoblast cell are autologous.
According to a further aspect of the invention there is provided an isolated chimeric cell wherein said cell is the product of a fusion between a first cell, or part thereof, which is a cytotrophoblast cell that expresses HLA-G and HLA class I antigen and a second cell wherein said first and second cell are derived from the same species.
Methods that promote the fusion of cells are well known in the art (Kennett, R.H.
(1979). Cell Fusion in: Cell Culture, Methods in Enzymology. (eds. Jakoby, W.B., and Pastan, I.H.) Academic Press San Diego, 58, 345-359 which is incorporated by reference in its entirety). It is also well known that cell hybrids may be formed by fusing the cytoplasm of a cell (in which the nucleus has been removed) with a selected intact cell to form a so called cybrid (Ege, T., Zeuthen, J., Ringertz, N.R.
(1973). Cell fusion with enucleated cytoplasms. Nobel, 23, 189-194; Veomett, G., Prescott, D.M., Shay, J., Porter, K.R. (1974). Reconstruction of mammalian cells from nuclear and cytoplasmic components separated by treatment with cytocholasin B. Proc Nat Acad Sci, 71, 19992002; Wright, W.E., and Hayflick L. (1975). Use of biochemical lesions for selection of human cells with hybrid cytoplasms. Proc. Nat.
Acad. Sci (LISA). 72, 1812-1816 which are incorporated by reference in their entirety). This has enabled investigation into nucleo-cytoplasmic interactions and, in particular, the influence of cytoplasmic determinants on nuclear gene expression. It has been known for several years that selected chemical treatments of cells in culture can result in cells extruding nuclei resulting in the formation of separate nuclear and cytoplasmic parts termed karyoplasts and cytoplasts, respectfully. These sub-cellular components have been used in fusion experiments. For example, it is possible to: * * produce a cytoplast from one cell and fuse the cytoplast to a selected cell to form a: cytoplasmic hybrid or cybrid. In addition it is also possible to fuse the karyoplast or cell with a selected cell to form a nuclear hybrid. The nuclei fuse after nuclear: membrane breakdown during mitosis and reconstitute after cytokinesis to form a polyploid or anueploid nucleus. The fusion of embryonal stem cells is described in S...
S S
Duran C, Talley PJ, Walsh J, Pigott C, Morton JE, and Andrews PW. Hybrids of pluripotent and nullipotent human embryonal carcinoma cells: partial retention of a pluripotent phenotype. Tnt J Cancer. 2001 Aug 1; 93(3):32432 which is incorporated by reference in its entirety.
In a preferred embodiment of the invention said chimeric cell comprises a cytoplasmic part derived from a cytotrophoblast cell and a nucleus derived from a cell that is not a cytotrophoblast cell.
In an alternative preferred embodiment of the invention said chimeric cell comprises a nucleus derived from a cytotrophoblast cell and a cytoplasmic part derived from a cell that is not a cytotrophoblast cell.
In a preferred embodiment of the invention the first and second cells are human cells.
In a further preferred embodiment of the invention said second cell is selected from the group consisting of: an epidermal keratinocyte; a fibroblast (e.g. dermal, cornea!; intestinal mucosa, oral mucosa, bladder, urethral, prostate, liver) an epithelial cell (e.g. corneal, dermal, corneal; intestinal mucosa, oral mucosa, bladder, urethral, prostate, liver); a neuronal glial cell or neural cell; a hepatocyte stellate cell; a mesenchymal cell; a muscle cell (cardiomyocyte, or myotube cell); a kidney cell; a blood cell (e.g. CD4+ lymphocyte, CD8+ lymphocyte; a pancreatic 3 cell; or an endothelial cell.
According to a further aspect of the invention there is provided a cell culture comprising a chimeric cell according to the invention.
According to a further aspect of the invention there is provided a method for the production of a chimeric cell comprising the steps of: S...
i) forming a preparation comprising a first cell which is a 0**S cytotrophoblast cell that expresses HLA-G and HLA class I antigen. ....
S I S S. *
and a second cell wherein said first and second cells are derived from the same species; and ii) providing conditions wherein said first and second cells fuse to form a chimeric cell.
According to a further aspect of the invention there is provided a chimeric cell according to the invention for use in the manufacture of a cell composition for the modulation of cellltissue rejection in transplantation therapy.
According to a further aspect of the invention there is provided a method to treat a condition that would benefit from transplantation therapy comprising administering a chimeric cell according to the invention.
Throughout the description and claims of this specification, the words "comprise" and "contain" and variations of the words, for example "comprising" and "comprises", means "including but not limited to", and is not intended to (and does not) exclude other moieties, additives, components, integers or steps.
Throughout the description and claims of this specification, the singular encompasses the plural unless the context otherwise requires. In particular, where the indefinite article is used, the specification is to be understood as contemplating plurality as well as singularity, unless the context requires otherwise.
Features, integers, characteristics, compounds, chemical moieties or groups described in conjunction with a particular aspect, embodiment or example of the invention are S....
to be understood to be applicable to any other aspect, embodiment or example described herein unless incompatible therewith.
An embodiment of the invention will now be described by example only and with S...
reference to the following Figures: S... * I * * I. *
Figure 1 illustrates the derivation and initial characteracterisation of human CTBS cell lines; (A) Histogram of hCG concentration in culture medium in 96-wells containing single embryoid bodies.(B)Adherent epithelial CTBS cells in TS' culture without feeder cells. Bars = 20 pm throughout. (C) Adherent multinucleated syncytiotrophoblast in same culture as (B). (D) & (E) adherent CTBS cells under phase contrast and UV light displaying cytokeratin (green) and hCGI3 (red/orange) immunolocalisation (nucleus, blue). (F) & (G) Single CTBS cells fusing to adherent multinucleated syncytium under phase contrast and LTV. Single cells mainly cytokeratin + and syncytium mainly hCG. (H) Adherent GFPsyncytial trophoblast (phase contrast and UV) and (1) UV alone. Inset low power of GFP-trophob last vesicles; Figure 2 illustrates RT-PCR and FACS analysis of TS cells. (A) Gene expression (RT-PCR) for undifferentiated HESCs (H7) and CTBS 1 and 2 cell lines. (B) FACS analysis profile for CTBS2 (similar data for CTBS1 not shown) in early culture. A proportion of cells express non classical HLA-G (peak A) while the majority express all forms of HLA class 1. Phase-contrast and immunofluorescent labelling of cells used for FACs analysis indicating HLA-G staining. Bar =20 jim; Figure 3 illustrates the differentiation of CTBS cell line to endovascular cells in TS' conditioned medium. A) Phase contrast micrograph of single adherent cytotrophoblast of CTBS1 cell line. B) The cells in (A) after 12 weeks in culture.
Long aggregates display typical endothelial-like morphology. (C) Dark field, low power micrograph of culture flask. D) Phase-contrast of endovascular cell aggregate displaying co-expression of HLA-G (E) and PECAM-1 (F). (G) Phase contrast of multinucleated giant' adjacent to endovascular cell. B) E.cadherin 0*t*** immunolocalisation was much greater in giant cells than endovascular cells; and: *:* Figure 4 illustrates CTBS spheroids in extracellular matrix and endometrial co- *.
culture. (A) CTBS spheroid (CTBS 1 cell line) in Matrigel culture for 5 days with * a...
long microvilli protrusions of syncytium. Inset (i) and (ii): higher magnification.::: phase contrast and immunostaining displaying cytokeratin(green) and hCG3 (red) in syncytial bed. Bar 100 rim. (B) Images from time-lapse movie (see supplementary information) of CTBS I aggregate in co-culture with endometrial stromal cells; bar = jim. Black arrow throughout indicates direction of migration of vesicle. (1), white arrow indicates invasive cytotrophoblast outgrowth; (4 and 5), white arrow indicates stromal erosion site; (4) inset (i) and (ii), higher magnification of margin at erosion site showing phase contrast and MMP-2 immunolocalisation. (C) CTBS - GFP cells in co-culture with endometrial stroma; bar =20 jim.
Materials and Methods Reverse transcription and polymerase chain reaction(RT-PCR).
Polymerase chain reaction (PCR) tecimique is used to identify genetic markers that are characteristic to cell type. Total RNA (2 jig) was reverse transcribed using I jig oligo-dT primer with MMLV ReverseTranscriptase (Promega) in a 40 jil reaction volume containing 1.25 mM dNTPs at 37 C. PCR was performed using ijil of cDNA in 50 j.tl reaction volume containing 15 pmol of each primer, 0.2 mM dNTPs and 1 unit Taq polymerase (Promega). Primer sequences used and conditions of these reactions were as follows: /3-actin-F: 5 -ATCTGGCACCACACCTTCTACJ&TGAGCTGCG...3'.
/3-actin-R:5 -CGTCATACTCCTGCTTGCTGATCCACATCTGC...3' (60 C annealing, x23 cycles).
Oct4-F: 5' CGACCATCTGCCGCTTTGAG-3' Oct4-R: 5'-CCCCCTGTCCCCCATTCCTA..3' (60 C annealing, x23 cycles). :...:.
Sox2-F: 5 -CCCCCGGCGGCAATAGCA...3'; : :* Sox2-R: 5'-TCGGCGCCGGGGAGATACAT.. 3' (60 C annealing, x38 cycles).
FGF4-F: 5' CTACAACGCCTACGAGTCCTACA...3'; FGF4-R: 5'GTTGCACCAGAAAAGTCAGAGTTG -3' (56 C annealing, x40 cycles).
Nanog-F: 5 -GCCTCAGCACCTACCTACCC-3' Nanog-R: 5'-GGTTGCATGTTCATGGAGTAG-3' (60 annealing and x30 cycles).
Eomes-F: 5 -TCACCCCAACAGAGCGAAGAGG3'; Eomes-R: 5'AGAGATTTGATGGAAGGGGGTGTC-3' (57 C annealing, x35 cycles).
Cdx2-F: 5' -CCTCCGCTGGGCTTCATTCC-3'; Cdx2-R: 5' TGGGGGTTCTGCAGTCTTTGGTC3' (60 C annealing, x3 5 cycles); HLA-G-F: 5 GCGGCTACTACAACCAGAGC-3'; HLA-G-R: 5'-GCACATGGCACGTGTATCTC3' (55 C annealing, x26 cycles).
CD9-F: 5'- TTGGACTATGGCTCCGATTC-3'; CD9-R: 5'-GATGGCATCAGGACAGGACT-3' (55 C annealing, x26 cycles).
CK7-F: 5 -ACAGAGCTGCAGTCCCAGAT-3' CK7-R: 5'-GTAGGTGGCGATCTCGATGT-3' (55 C annealing, x26 cycles).
Fluorescence activated cell sorting (FACS) Trophoblast cells were prepared for cell sorting by dissociating CTBS cells into single cells with Trypsin-EDTA. Cells were resuspended at 5 x106/ml in FACS buffer with 40% normal goat serum to block on ice for 20 minutes. 90 p.1 of the cell suspension were aliquoted into FACS tube and 10 p.1 of G233 (TS marker for HLA- G) and W6/32 HLA-Class I control was added. G233 supematant with NaN3 (mouse IgG2a) was kindly given by Dr Ashley King, University of Cambridge. The cells were incubated on ice for 30 minutes. After incubation, the cells were washed twice before being labelled with anti-mouse polyvalent immunoglobulin FITC conjugate for 30 * minutes on ice. The cells were washed again and resuspended in 300 p.1 buffer. * :* : Determination of hCGI3 concentration in cell cultures. S...
Concentrations of hCGI3 were determined using a sandwich enzyme immunoassay kit (Cat. # EIA-1469, DRG Diagnostics). The standards and the samples were incubated *I* with 100 p.1 anti-hCG enzyme-conjugate for 30 minutes at room temperature followed by a five times washing procedure. A second incubation with 100 i substrate solution for 10 minutes was stopped with the addition of 50 1 stop solution. Absorbance was read at 450 10 rn-n with a microtitre plate reader. The concentration of hCGj3 in the samples was determined from the standard curve as m I.U./mI.
Constitutive expression of eGFP in HESCs A pCAG-GFP expression vector was constructed by excision of eGFP from pEGFP- 1 (Clontech) with XhoI and NotI and insertion into the pCAG vector16. H7 cells were seeded at the equivalent of 2x 1 per well of a 6-well plate on Matrigel. The next day they were transfected using ExGen 500 (Fermentas) according to the manufacturer's instructions. The DNAINaC1 Exgen mixture was then added directly to the normal growth medium in the well. The plate was centrifuged at 280 g for 5 minutes and placed back in the incubator. The medium was exchanged the next day with hES growth medium containing puromycin (at lug/mi). Viable colonies were picked after 2-3 weeks.
Endometrial - CTBS spheroid co-culture.
Luteal phase endometrial biopsies were obtained from women undergoing hysterectomy under full ethical approval and patient consent. Endometrial epithelial and stromal cells were isolated using a method described previousl4. Preparations were embedded in Matrigel on membrane inserts and primed with progesterone for 24 hours before the start of co-culture with CTBS. In monolayer co- culture, CTBS spheroids were cultured on a confluent layer of stromal or epithelial cells in culture wells. The co-cultures were maintained in 500 jii of either conditioned TS medium or serum-free HES medium up to six days. :. : *:.
Time-lapse Microscopy Adherent CTBS cultures or CTBS-endometrial cocultures were continuously monitored under an inverted microscope in a humidified physiological chamber at 37 C in 5% CO2 in air (DigitalPixel Ltd) for up to three days. Preliminary * 0 * ** * experiments indicated no difference in the viability of cells maintained under these conditions compared to a standard incubator. Regions of interest (ROT) were identified and programmed for analysis using Simple PCI software (C-Imaging) with control over xyz scan, transmitted light, and image capture. Routinely 20 ROIs were identified with image capture every 15 minutes.
1. Movie of adherent multinuclear TS cells exhibiting cell fusion 2. Movie of TS vesicle attached and migrating on endometrial stromal cells in co-culture and displaying erosion site.
Example 1
First, we generated trophoblast - containing EBs, using HESCs (H7 and H14) of normal karyotype, which were maintained and passaged by standard protocols using serum-replacement medium (8,9). EBs were prepared by aggregation of single HESCs (dissociated with 1 mg/ml collagenase IV) in ES medium without basic fibroblast growth factor in Petri dishes in 5% CO2 in air. On day 5, EBs were then transferred singly to wells of a 96- well culture plate and cultured for a further three days before aliquots of medium were subjected to ELISA assay as described previously (10). HCGI3 was detected in most wells (4 x 96 well plates) but only 3.8% of wells had concentration of hormone greater than 500 m T.U./ ml (figure 1A) . The BBs in these wells were of equivalent size and morphology, indicating that any increase in hCGf3 was likely to be due mainly to the proportion of trophoblast cells rather than a greater overall number of cells. *
**s**. *
EXAMPLE 2
To select for CTBS cells, BBs exhibiting high hCGf3 secretion were subjected to: **** several rounds of selective enrichment by growth in TS' medium comprising conditioned medium from fibroblast feeders supplemented with fibroblast growth factor 4 (FGF4) and heparin. TS medium promotes differentiation of murine trophoblast stem cells from extra-embryonic ectoderm (4). Those BBs maintaining a high secretion of hCGI3 were pooled, disaggregated and allowed to form new EBs and this enrichment protocol repeated consecutively for three rounds until all BBs displayed consistently high hCGI3 secretion. EBs were disaggregated (0. 25% trypsin- EDTA) and then single cells allowed to proliferate in adherent culture in TS medium without feeders. Control cultures of EBs in HES medium without bFGF exhibited only basal hCGt3 levels indicating poor trophoblast differentiation. Initially, four cell lines were generated with variable proliferation, two of which have maintained persistent proliferative capacity for more than 30 passages (CTBS 1 from 117 HESC and CTBS2 from H14 HESC) and form epithelial-like cell colonies with single and multinucleated cells (figure 1B). An additional CTBS cell line (CTBS-GFP1) was generated by the same methods but from H7 HESCs with constitutive expression of enhanced green fluorescent protein, eGFP (11) (figure 1H and 11). Continuous proliferation of each cell line was related to the persistence of a mononuclear cytotrophoblast population (relative to syncytium formation) as determined by immunostaining for cytokeratin and hCGI3 (figure 1D-G). Cell proliferation was maintained by regular cell passage every 5 days as this inhibited terminal differentiation. When CTBS cells were aggregated and returned to mouse embryonic fibroblast feeders with HES medium they failed to revert to or generate either HESC colonies or EBs with pluripotent developmental capacity other than trophoblast. This indicated the absence of residual HESCs in the cell lines and the likely restricted developmental capacity of CTBS cells as has been shown for the mouse (10). * *
S S. * * S.
EXAMPLE 3
We confirmed the trophoblast phenotype of the cell lines by immunolocalisation of the pan trophoblast marker cytokeratin 7 (12, 13), Stage-Specific Embryonic * ...
Antigen 1 (SSEA1, 4), and human placental lactogen (hPL, 14). Additionally, reverse S... **I.
S S *5 S
transcription and the polymerase chain reaction (RT-PCR) were performed with primer sequences for marker genes of HESCs and trophoblast. Compared with HESCs, mIRNA expression for Oct 4, Sox2, FGF4, Nanog in the derived cell lines was absent while trophoblast- related mRNAs for Cdx2 (caudalrelated homeobox), Ck7, HLA- G, and Cd9 and were up regulated or maintained (figure 2A). The latter two arc known markers for extravillous cytotrophoblast which invades the uterine stroma (deciduas) during placentation (15). Surprisingly, eomesodermin (eomes), a marker of mouse early postimplantation trophoblast, was expressed strongly in HESCs but was weak or absent in the CTBS cell lines (figure 2A). Several reports have highlighted differences between mouse and human ESCs (4,16) including eomesodermin expression in HESCs but not mouse ES cells (16). Furthermore, the expression of some trophoblast markers in stock cultures of HESCs may relate to spontaneous differentiation to trophoblast lineage. We had previously shown that expression of trophectodermal markers in such cultures occurred predominantly in the SSEA (-) and SSEA1 (+) subsets of cells, consistent with their expression in the differentiated derivatives of the HESCs rather than in the HESCs themselves (4,16).
EXAMPLE 4
To further assess the subtype of trophoblast cells, the comparative cell surface expression of histocompatibility HLA class I (pan HLA antibody W6/32) and HLA-G (antibody G233) antigens was determined by fluorescent activated cell sorting (FACS) and immunolocalisation (14, 15, and 17). The majority of cells (- 90%) expressed HLA- class I histocompatibility antigens consistent with extravillous trophoblast (4, 15) (figure 2B). The expression of HLA-G (18) , the non-classical HLA-class I antigen also specifically expressed in anchoring extravillous cytotrophoblast of first trimester placentae (14, 15) was relatively weak in most cells, but a small proportion (1 0%) of cells displayed strong immunoreactivity (figure 2B and C). Some cells expressed vimentin, possibly indicating interstitial CTB (14). : Following extended culture for one week or more in 125 flasks, the proportion of HLA-G cells increased considerably (>90%). These cells exhibited distinct I... S * S *
endothelial cell morphology similar to cultures of differentiating cytotrophoblast from first trimester human placental tissue (15) and resembled endothelial morphological differentiation from primate embryonic stem cells (19,20).
Significantly, however, the cells co-expressed HLA-G and the platelet endothelial cell adhesion molecule-i (PECAM-i), both markers of invasive endovascular (endothelial-like) CTB (3,21, figure 3). E-cadherin immunolocalisation was weak on endovascular cells but strong on a relatively small proportion (<5%) of multinucleated cells also present at this stage and most likely equivalent to the syncytial giant cells found in stroma of the developing placenta.
EXAMPLE 5
To determine the functional capacity of CTB cells, we first investigated the formation of non-proliferative, syncytiotrophoblast by cell-cell fusion of villous cytotrophoblast (1). The spontaneous generation of syncytium in adherent cell cultures of CTBS1 was monitoring cells under an inverted microscope for up to 3 days in a chamber at 37 C in 5% CO2 in air by continuous time-lapse recording.
Adherent cells displayed progressive migration across the culture dish promoted by pseudopodial-like extension of cells. When cells occasionally converged they fused to form multi-cellular syncytiotrophoblast cells (figure 1G) that were hCG, and Ck7 positive but HLA class 1 negative. This cell fusion was captured unequivocally by digital time-lapse microscopy. *
S
EXAMPLE 6
Next, we examined the invasive implantation potential of the CTBS cell lines by adopting a three- dimensional spheroid culture. This technique has been shown to maintain extra villous CTB phenotype of first trimester placental tissue (22). ... * *. S Aggregates of CTBS cells were generated from confluent monolayers following brief trypsinisation and incubation in non-adherent culture for 5-10 days. When cultured in extracellular matrix (Matrigel) drops, these CTBS spheroid aggregates developed characteristic outgrowths, which expressed hCG and cytokeratin (figure 4Ai and ii).
The hCG receptor is expressed on invasive cytotrophoblast and similar observations have been reported for EB differentiation to trophoblast (15) . On further culture with primary human endometrial tissue (luteal phase) prepared using well-characterised protocols (23), CTBS aggregates attached to both epithelial cells and stromal cells.
Significantly, as shown by time-lapse microscopy (figure 4B) CTBS spheroids with stromal cell cultures displayed a characteristic circular migratory movement and exhibited polar outgrowths from which endovascular cells streamed After about 24- 36 hours in co-culture, these trophoblast outgrowths were the site of an erosion of the extracellular matrix of the stroma (and supplementary information, movie 2). This was identified by the rapid retraction of the trophoblast vesicle due to the dissolution of underlying extracellular matrix of the stromal cells (figure 4B, 2-5). A similar process of trophoblast invasion has been observed for human blastocyst co-culture with stromal cells in vitro (24). The erosion site was characterised by extravillous (HLA -G) trophoblast that expressed matrix metalloproteinase 2 (gelatinase A, figure 4b4, i and ii), identified recently as a key enzyme correlated with first trimester invasive capacity of human cytotrophoblast (25) and whose activity is altered in cytotrophoblast in women with pre-eclampsia (26). Single GFPtrophoblast cells with endometrial stroma in culture displayed a similar response.
These CTBS cell lines are the first distinct set of multipotent progenitor stem cell lines to be derived from HESCs and maintained independently. The method of l,.s..
selecting individual viable EBs with an appropnate secretory marker, followed by rounds of enrichment by the regeneration of BBs, could be applied in pnnciple to derive a range of other cell types. It has been shown previously that clonally derived HESCs maintain full pluripotency and proliferation (27) suggesting that CTBS cells a develop from a homogeneous HESC population rather than multiple (i.e. ES and TS) I.'' precursors. Hence, our findings differ from the mouse where trophoblast cells may be * e * 4* a derived from extra-embryonic ectoderm but not from murine ESCs without conditional gene expression (28).
We have derived, for the first time, human cytotrophoblast stem cell lines. These differ from immortalised placental lines in their capacity to differentiation into several cytotrophoblast subtypes including terminal differentiation of endovascular cells. Cell cultures therefore closely mimic the implantation process in vitro and represent an important new model of placental dysfunctions such as pre-eclampsia.
The efficient generation of endovascular cytotrophoblast also offers the prospect of using these cells for regenerative medicine. Their pseudovasculogenic and invasive characteristics might be utilised in a variety of cell therapies remote from the uterus but related to angiogenesis and vessel remodelling, especially as expression of HLA- G (17) and indoeamine 2,3, -dioxygenase (29,30) render the cells naturally refractory to immune rejection.
References 1. B. Pariaet al., Science 296, 2185 (2002).
2. S. Laird et al., Human Reprod. Update 9, 163 (2003).
3. K. Red-Horse eta!., J.Clin.Imvest. 114, 744 (2004).
4. S. Tanaka eta!., Science 282, 2072 (1998).
5. J. Henderson J. et al., Stem Cel!s 20, 329 (2002).
6. B. Gerami-Naimi et a!., Endocrino!ogy 145, 1517 (2004)..
7. R. Xu et a!., Nat. Biotech. 20, 1261 (2002) 210..
8. M. Matin et a!., Stem Ce!ls 22, 659 (2004). *
*..*S.
9. J. Thomson eta!., Science 282, 1145 (1998). :i:...
10. R. Nishimura et a!., Jpn. J. Cancer Res. 80, 968 (1989).
U U... n * S S S. *
11. T. Niwa et al., Mol. Cell Biol. 22, 1526 (2002).
12. E. Kam et al., Hum. Reprod.14, 2131 (1999).
13. T. Haigh et al., Placenta 20, 615 (1999).
14. A. King, L.Thomas, P.Bischof Placenta 21, S113 (2000).
15. T.Nagamatsu eta!., Placenta 25, 153 (2004).
16. I. Ginis et al., Dev. Biol. 269, 360 (2004).
17. Y. Loke, King, A. in Human Implantation, cell biology and immunology, (Cambridge University Press, Cambridge, 1995). pp 82-101.
18. S. Kovats et a!., Science, 248, 220 (1990).
19. S.Levenberg eta!., Proc.Natl.Acad.Sci. 99, 4391 (2002).
20. D. Kaufman et al., Blood 103, 1325 (2004).
21. C. Damsky, S. Fisher, Curr. Opin. Cell Biol. 10, 660 (1998).
22. T.Korff, T. Krauss, H.Augustin, Ex. Cell Res. 297, 415 (2004).
23. S. Laird, T.Li, A.Bolton, Hum. Reprod. 8, 795 (1993).
24. J. Carver et a!., Hum. Reprod. 18, 283 (2003).
25. E. Staun-Ram et al., Reprod. Biol. Endocrin. 2, 59 (2004) 26. S. Campbell et a!., Biol.Reprod. 71, 244 (2004) 27. M. Amit et a!., Dev. Biol. 227, 271 (2000).
28. H. Niwa, J. Miayazaki, A. Smith, Nat.Gen. 24, 372 (2000).
29. D. Munn eta!., Science 297, 1867 (2002) S....
30. A. Honig et a!., J.Reprod.Immunol. 61, 79 (2004). : * S.. S... S... * * . S.
Claims (1)
- Claims I. An isolated cytotrophoblast stem cell wherein said stem cellexpresses HLA- G and HLA class I antigen.2. A stem cell according to Claim 1, wherein said stem cell is mononuclear.3. A stem cell according to Claim 1 or 2, wherein said stem cell expresses at least one stem cell marker selected from the group consisting of: cytokeratin 7; stage specific embryonic antigen 1; human placental lactogen; caudal related homeobox; vimentin; and Cd9.4. A stem cell according to any of Claims 1-3, wherein said stem cell is isolated from a primate.5. A stem cell according to Claim 4, wherein said primate is human.6. A stem cell according to any of Claims 1-5, wherein said stem cell is genetically modified.7. A composition comprising a cytotrophoblast stem cell according to any of Claims 1-6, for use in tissue engineering.8. A culture comprising a cytotrophoblast stem cell according to any of Claims 1-6, wherein said culture is contained within a cell culture vessel.9. A spheroid body comprising a cytophoblast stem cell according to any of Claims 1-6 and a collagen based cell support matrix.*s..S.V * I...V **** S...S S S I. *10. A spheroid body according to Claim 9, wherein said tissue is isolated from a primate.11. A spheroid body according to Claim 10, wherein said primate is a human.13. A spheroid body according to any of Claims 9-11, wherein said cytotrophoblast stem cell in said spheroid body expresses at least one metalloprotease.14. A spheroid body according to Claim 13, wherein said metalloprotease is metalloprotease 2.15. A method to derive human cytotrophoblast stem cells comprising selectively enriching for cytotrophoblast stem cells that express HLA-G and HLA class 1 antigen.16. A method to derive human cytotrophoblast stem cells from embryonic stem cells comprising the steps of: i) forming embryoid bodies comprising cytotrophoblast cells in a cell culture vessel; ii) identifying those embryoid body cultures which produce greater than about 500m I.U./ml chorionic gonadotrophin; iii) culturing the embryoid bodies identified in (ii) in conditioned media from fibroblast feeder cells; iv) pooling those embryoid bodies which produce greater than about 500m I.U./ml chorionic gonadotrophin and disaggregating said embryoid bodies; and v) repeating (iv) until substantially all embryoid bodies produce high levels of chorionic gonadotrophin. : .*. S... SSS* S...S S S S. *17. A method according to Claim 16, wherein said conditioned media comprises fibroblast growth factor 4 and heparin.18. Spent medium produced by culturing the cytotrophoblast stem cells according to any of Claims 15-17.19. A method to produce endovascular cytotrophoblast cells comprising the steps of: i) providing a preparation of cytotrophoblast stem cells according to any of claims 1-6; ii) selecting from said preparation a population of cells that express both HLA-G and platelet endothelial cell adhesion molecule-i.20. A method according to Claim 19, wherein said selected cells further express Von Willebrand Factor.21. A method according to Claim 19 or 20, wherein said preparation is cultured under high oxygen tension, preferably at least 5% CO2.22. An endovascular cytotrophoblast cell obtained or obtainable by the method according to any of Claims 19-21.23. An in vitro method for the formation of spheroids comprising cytotrophoblast stem cells comprising: i) providing a cell culture vessel comprising: a) cytotrophoblast stem cells according to any of Claims 1-6; b) cell culture medium; and ii) providing conditions which promote the growth and differentiation of said cytotrophoblast stem cells in said spheroid. : *... eS S S S. 524. Spent medium produced by culturing the spheroids comprising cytotrophoblast stem cells according to Claim 23.25. A method for the identification of genes associated with cytotrophoblast stem cell differentiation comprising the steps of: i) providing a preparation comprising at least one cytotrophoblast stem cell according to any of Claims 1-6; ii) extracting nucleic acid from said cell preparation; iii) contacting said extracted nucleic acid with a nucleic acid array; and iv) detecting a signal which indicates the binding of said nucleic acid to a binding partner on said nucleic acid array.26. A method according to Claim 25 wherein said method includes the additional steps of: i) collating the signal(s) generated by the binding of said nucleic acid to said binding partner; ii) converting the collated signal(s) into a data analysable form; and optionally iii) providing an output for the analysed data.27. A method according to Claim 25 or 26, wherein said method includes a comparison of the array signal produced between different populations of cytotrophoblast stem cells isolated from different animal subjects.28. A method for the preparation of a library comprising cytotrophoblast stem cell specific gene expression products comprising the steps: i) providing a preparation comprising a cytotrophoblast stem cell according to any of Claims 1-6; ii) extracting nucleic acid from said cell preparation; S.....iii) preparing a cDNA from ribonucleic acid contained in said extracted nucleic acid; and iv) ligating eDNA formed in (iii) into a vector. *0** S. ..29 *:::: a...S S SS29. A method according to Claim 28, wherein said vector is a phage based vector.30. An in vitro method to analyse the invasive properties of cytotrophoblast stem cells comprising the steps of: i) providing a spheroid according to any of Claims 9-14 and endometrial tissue; and ii) monitoring the invasive phenotype of cytotophoblast cells with respect to said endometrial tissue.31. A method to identify agents that modulate the angiogenic activity of endothelial cells comprising the steps of: i) providing a preparation of endovascular cytotrophoblast cells according to Claim 22 and an agent to be tested; ii) determining the effect, or not, of the agent on the proliferation andlor motility of said endovascular cytotrophoblast cells.32. A method according to Claim 31 wherein said agent is an antagonist.33. A method according to Claim 31 wherein, said agent is an agonist.34. The use of a cytotrophoblast stem cell, or a cell derived from a cytotrophoblast cell according to any of claims 1-6, in the manufacture of a cell composition for use in the modulation of the immune system.35. The use of a cytotrophoblast stem cell, or a cell derived from a cytotrophoblast stem cell, according to any of claims 1-6, in the manufacture of a cell composition for use in the modulation of cell/tissue rejection in transplantation S.....therapy. :**.*.36. Use according to claim 34 or 35 wherein said cell is a mammalian cell, S... S...S S *. S37. Use according to claim 36 wherein said cell is a human cell.38. A composition comprising an isolated mammalian cytotrophoblast stem cell, or a cell derived from a cytotrophoblast stem cell, and at least one further isolated mammalian cell that is not a mammalian cytotrophoblast stem cell.39. A composition according to claim 38 wherein said mammalian cell is a human cell.40. A composition according to claim 39 wherein said mammalian cell is selected from the group consisting of: an epidermal keratinocyte; a fibroblast cell; an epithelial cell; a neuronal glial cell; neural cell; a hepatocyte stellate cell; a mesenchymal cell; a muscle cell; a kidney cell; a blood cell; a pancreatic 3 cell; or an endothelial cell.41. A composition according to claim 40 wherein said cell is a pancreatic cell.42. A composition according to claim 39 wherein said mammalian cell is a stem cell.43. A composition according to claim 42 wherein said stem cell is selected from the group consisting of: a haemopoietic stem cell; a neural stem cell; a bone stem cell; a muscle stem cell; a mesenchymal stem cell; an epithelial stem cell; an endodermal stem cell; an embryonic stem cell; an embryonic germ cell.44. A composition according to claim 43 wherein said mammalian cell is an embryonic stem cell or an embryonic germ cell. e * S S45. A composition according to any of claims 38-44 wherein said mammalian cell and said cytotrophoblast stem cell are autologous. S... S... S... S * S. *46. A composition according to any of claims 3 8-44 wherein said composition comprises an additional agent wherein said agent is an immunosuppressant.47. A vehicle wherein said vehicle includes a mammalian cytotrophoblast stem cell, or a cell derived from a cytotrophoblast stem cell according to any of claims 1-6, and at least one further isolated mammalian cell that is not a mammalian cytotrophoblast stem cell.48. An isolated chimeric cell wherein said cell is the product of a fusion between a first cell, or part thereof, which is a cytotrophoblast stem cell according to any of claims 1-6 and a second cell wherein said first and second cell are derived from the same species.49. A chimeric cell according to claim 48 wherein said cell comprises a cytoplasmic part derived from a cytotrophoblast stem cell and a nucleus derived from a cell that is not a cytotrophoblast stem cell.50. A chimeric cell according to claim 48 wherein said cell comprises a nucleus derived from a cytotrophoblast stem cell and a cytoplasmic part derived from a cell that is not a cytotrophoblast cell.51. A chimeric cell according to any of claims 48-50 wherein the first and second cells are human cells.52. A chimeric cell according to any of claims 48-51 wherein said second cell is selected from the group consisting of: an epidermal keratinocyte; a fibroblast; an epithelial cell; a neuronal glial cell or neural cell; a hepatocyte stellate cell; a S.....mesenchymal cell; a muscle cell; a kidney cell; a blood cell; a pancreatic cell; or: * an endothelial cell.IS 32..S SSS S53. A cell culture comprising a chimeric cell according to any of claims 48-52.54. A method for the production of a chimeric cell comprising the steps of: i) forming a preparation comprising a first cell which is a cytotrophoblast stem cell according to any of claims 1-6 and a second cell wherein said first and second cells are derived from the same species; and iii) providing conditions wherein said first and second cells fuse to form a chimeric cell.55. A chimeric cell according to any of claims 48-52 for use in the manufacture of a cell composition for the modulation of cell/tissue rejection in transplantation therapy.56. An isolated cytotrophoblast stem cell wherein said stem cell expresses HLA- G antigen. * * S....S S. * ** SS *S33 *****. S... I*
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0507755.7A GB0507755D0 (en) | 2005-04-16 | 2005-04-16 | Cytotrophoblast stem cells |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| GB0606875D0 GB0606875D0 (en) | 2006-05-17 |
| GB2425129A true GB2425129A (en) | 2006-10-18 |
| GB2425129B GB2425129B (en) | 2008-11-05 |
Family
ID=34630823
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB0507755.7A Ceased GB0507755D0 (en) | 2005-04-16 | 2005-04-16 | Cytotrophoblast stem cells |
| GB0606875A Expired - Fee Related GB2425129B (en) | 2005-04-16 | 2006-04-06 | Cytotrophoblast stem cell |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB0507755.7A Ceased GB0507755D0 (en) | 2005-04-16 | 2005-04-16 | Cytotrophoblast stem cells |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN101218342A (en) |
| GB (2) | GB0507755D0 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103114075B (en) * | 2013-01-18 | 2014-11-12 | 内蒙古大学 | Cattle trophoderm stem cell system establishment method |
| US20160326487A1 (en) * | 2014-01-08 | 2016-11-10 | Samsung Life Public Welfare Foundation | Stem Cells Derived from Pure Chorionic Trophoblast Layer and Cell Therapy Comprising Same |
| CN104946581B (en) * | 2015-04-28 | 2017-10-13 | 广东温氏食品集团股份有限公司 | A kind of special culture media and method for cultivating pig cytotrophoblast stem cells |
| CN111304156A (en) * | 2020-02-20 | 2020-06-19 | 南方医科大学南方医院 | Induced trophoblast stem cell and preparation method and application thereof |
| CN116286666B (en) * | 2023-05-15 | 2023-08-04 | 成都云测医学生物技术有限公司 | Trophoblast cell, preparation method and application thereof, and method for amplifying NK cell |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996031604A1 (en) * | 1995-04-07 | 1996-10-10 | The Regents Of The University Of California | Antibodies for the detection of hla-g |
| WO2000017325A1 (en) * | 1998-09-23 | 2000-03-30 | Mount Sinai Hospital | Trophoblast cell preparations |
| WO2003078599A2 (en) * | 2002-03-15 | 2003-09-25 | Wicell Research Institute, Inc. | Method for generating primate trophoblasts |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2960328A1 (en) * | 2004-11-04 | 2015-12-30 | Ocata Therapeutics, Inc. | Derivation of embryonic stem cells |
| US7642091B2 (en) * | 2005-02-24 | 2010-01-05 | Jau-Nan Lee | Human trophoblast stem cells and use thereof |
-
2005
- 2005-04-16 GB GBGB0507755.7A patent/GB0507755D0/en not_active Ceased
-
2006
- 2006-04-06 CN CN200680021795.8A patent/CN101218342A/en active Pending
- 2006-04-06 GB GB0606875A patent/GB2425129B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996031604A1 (en) * | 1995-04-07 | 1996-10-10 | The Regents Of The University Of California | Antibodies for the detection of hla-g |
| WO2000017325A1 (en) * | 1998-09-23 | 2000-03-30 | Mount Sinai Hospital | Trophoblast cell preparations |
| WO2003078599A2 (en) * | 2002-03-15 | 2003-09-25 | Wicell Research Institute, Inc. | Method for generating primate trophoblasts |
Non-Patent Citations (4)
| Title |
|---|
| Endocrinology (2004), Vol 145, pp 1517-1524, "Trophoblast differentiation in embryoid bodies...", Gerami-Naini et al * |
| Journal of Clinical Investigation (1997), Vol 99, pp 2139-2151, "Human cytotrophoblasts adopt a...", Zhou et al * |
| Journal of Immunology (1995); Vol 154, pp 3771-3778, "Human placental HLA-G expression is...", McMaster et al * |
| Science (1998), Vol 282, pp 2072-2075, "Promotion of trophoblas stem cell...", Tanaka et al * |
Also Published As
| Publication number | Publication date |
|---|---|
| GB2425129B (en) | 2008-11-05 |
| GB0507755D0 (en) | 2005-05-25 |
| CN101218342A (en) | 2008-07-09 |
| GB0606875D0 (en) | 2006-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20080213387A1 (en) | Cytotrophoblast Stem Cell | |
| Harun et al. | Cytotrophoblast stem cell lines derived from human embryonic stem cells and their capacity to mimic invasive implantation events | |
| AU2023203677A1 (en) | Immune cell organoid co-cultures | |
| WO2017047799A1 (en) | Culture method for differentiating primordial germ cells into functionally mature oocytes | |
| US20050032207A1 (en) | Method for isolating, culturing and differentiating intestinal stem cells for therapeutic use | |
| AU2010244121B2 (en) | Lung tissue model | |
| US9850466B2 (en) | Somatic cells with innate potential for pluripotency | |
| HUE029316T2 (en) | Lung tissue model | |
| WO2005090557A1 (en) | Method of proliferating pluripotent stem cell | |
| CA2434362A1 (en) | Pluripotent adult stem cells derived from regenerative tissue | |
| WO2001053465A9 (en) | Human embryoid body-derived cells | |
| Bai et al. | Establishment of human induced trophoblast stem-like cells from term villous cytotrophoblasts | |
| James et al. | Modelling human placental villous development: designing cultures that reflect anatomy | |
| GB2425129A (en) | Cytotrophoblast stem cells | |
| EP2670842A2 (en) | Methods for making cells with an extra-embryonic endodermal precursor phenotype | |
| JP2004537999A (en) | Cell culture method for obtaining prostate-like glands | |
| JP2018183137A (en) | Method for preparing a kidney structure with collecting duct arborized from pluripotent stem cells | |
| WO2010039781A1 (en) | Method for dedifferentiating melanocytes | |
| WO2008051949A2 (en) | Gpr125 as a marker for stem and progenitor cells and methods use thereof | |
| Rielland et al. | Early alteration of the self-renewal/differentiation threshold in trophoblast stem cells derived from mouse embryos after nuclear transfer | |
| KR20240056604A (en) | Method for producing committed cardiac progenitor cells | |
| Ganeva | Acquisition of renogenic competence in the early mouse embryo and embryonic stem cells | |
| Rovira Clusellas et al. | Murine ES-derived pancreatic acinar cells recapitulate features of early pancreatic differentiation | |
| Udayashankar et al. | 17 Models of Trophoblast Development and Embryo Implantation Using Human Embryonic Stem Cells | |
| Fu et al. | Chimerization of human ESC-derived extraembryonic cells with the mouse blastocyst |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 732E | Amendments to the register in respect of changes of name or changes affecting rights (sect. 32/1977) |
Free format text: REGISTERED BETWEEN 20110324 AND 20110330 |
|
| PCNP | Patent ceased through non-payment of renewal fee |
Effective date: 20140406 |